United States: House Passes 21st Century Cures Act: What Does It Mean For Clinical Research?

On July 10, 2015, the U.S. House of Representative passed H.R. 6, the 21st Century Cures Act, with strong bipartisan support in a vote of 344-77. As Ropes & Gray has summarized Cures Act provisions related to Medicare and Medicaid, FDA regulatory and digital health in separate Alerts, the bill contains significant changes to FDA's regulation of drugs and devices as part of medical innovation reform, as well as modifications to Medicare and Medicaid programs. The bill includes several provisions related to federal oversight of clinical research, with implications for a wide range of stakeholders across the life sciences and health care industries, including drug and device manufacturers, hospitals, academic medical centers, universities/medical schools, institutional review boards, and contract research organizations.

Potential Impact of 21st Century Cures Act on Clinical Research

The Clinical Research provisions of the House-passed version of the 21st Century Cures Act signal a trend by Congress to minimize unnecessary and duplicative administrative (including federal and institutional) requirements, and to promote the broad availability of clinical research data, with adequate security and privacy measures, to advance medical product innovation. The bill also contains a provision to facilitate and encourage the inclusion of underrepresented subpopulations in clinical research.

Several key provisions relevant to Clinical Research:

  • Streamlining Clinical Trials [Section 2261]. This provision would simplify and facilitate researcher compliance by harmonizing differences, to the extent possible and consistent with statute, between the HHS Human Subject Regulations (45 CFR Part 46) and FDA Human Subject Regulations (21 CFR Parts 50, 56, 312, and 812). The agencies would be instructed to modify regulations and relevant guidance documents to reduce regulatory duplication and unnecessary delays, facilitate multisite research, and incorporate local considerations, community values, and protections of vulnerable populations. The revised regulations and guidance would delineate IRB roles during multisite research, as well as clarify requirements and policies related to the regulatory and legal liability concerns of a sponsor when relying on local IRBs for multisite research.
  • Central IRB Review [Section 2262]. This provision would delete the requirement that medical device studies be overseen by a "local" IRB. By striking "local," this provision would allow all clinical trials of FDA-regulated medical products to be overseen by a central IRB. FDA previously allowed for central IRB review of drug and biological product studies. With this provision, medical device studies also would be eligible for central IRB oversight.
  • Waiver of Informed Consent for Minimal Risk Research with Appropriate Safeguards [Section 2263]. This provision would modify the investigational drug and device requirements to allow for waiver of informed consent if the proposed clinical testing poses no more than minimal risk to human subjects and includes appropriate safeguards to protect subjects' rights, safety, and welfare. Currently, a significant difference between FDA and HHS Human Subject Regulations is the authority of an IRB in the Common Rule, which is absent in FDA regulations, to waive consent for certain minimal risk research. With this new provision, Congress would allow FDA to harmonize with the Common Rule by permitting an IRB to waive informed consent for FDA-regulated minimal risk research if the subjects are adequately protected. FDA rule-making would predictably reflect the safeguards contained in the Common Rule, such as the requirements that the waiver of consent will not adversely affect the rights and welfare of the subjects, that the research could not practicably be carried out without the waiver, and that, whenever appropriate, the subjects will be provided with additional pertinent information after the study ends.
  • Standardization of Data in Clinical Trial Registry Data Bank on Eligibility for Clinical Trials [Section 1101]. This provision would amend the statute authorizing www.ClinicalTrials.gov, by requiring NIH to ensure that the registry and results databank is configured in a way easily used by the public and is in a standardized format that identifies the disease studied and each study's inclusion and exclusion criteria. Those process changes are intended to facilitate lay use as well as communication between the databank and electronic health records and other relevant health information technologies.
  • Facilitating Collaborative Research with Greater Data-Sharing [Sections 1121 and 1122]. This subtitle would establish a pilot program to make available certain de-identified data from qualified clinical trials, with appropriate security measures in effect, for further study of such data by scientific and medical researchers. This subtitle also establishes a National Neurological Diseases Surveillance System to track and record scientific information related to the epidemiology, natural history, prevention, detection, management, and treatment of neurological diseases, such as multiple sclerosis and Parkinson's disease. The information in the System, with appropriate privacy and security protections, will be made available to the public, including researchers.
  • Grants to Collect Data on Natural History of Diseases [Section 1123]. This provision would encourage FDA to enter into public-private partnerships and award grants to patient advocacy groups to establish and facilitate information collection and analysis regarding the natural history of diseases, with a particular focus on rare diseases. The partnerships' data relating to the natural history of diseases would be made available, as appropriate, to the public (including researchers and drug developers) to help facilitate and expedite medical product development programs.
  • Accessing, Sharing, and Using Health Data for Research Purposes [Section 1124]. This provision would require HHS to amend the HIPAA Privacy Rule to: (1) allow the use and disclosure of protected health information by a covered entity for research purposes, including for studies whose purpose is to obtain generalizable knowledge, to be treated as the use and disclosure of such information for "health care operations"; (2) include research activities related to the quality, safety, or effectiveness of an FDA-regulated product as a public health activity to allow a covered entity to disclose protected health information under certain conditions; and (3) permit remote access to health information by a researcher if appropriate security and privacy safeguards are maintained and if the protected health information is not retained by the researcher.
  • Reducing Administrative Burdens on Researchers [Section 1023]. This provision would require NIH to develop a policy to reduce administrative burdens on researchers who are funded by NIH, with input from the National Academy of Sciences and the Scientific Management Review Board. Within two years after enactment of the Act, NIH would be required to submit a report to Congress detailing how NIH has implemented the policy measures.
  • Increasing Inclusion of Underrepresented Communities in Clinical Trials [Section 1029]. This provision would express the opinion of Congress that the National Institute on Minority Health and Health Disparities include within its strategic plan ways to increase representation of underrepresented communities in clinical research. This provision would be consistent with IRBs' mandate to ensure that the selection of subjects is equitable.
  • Promoting Pediatric and Geriatric Research through NIH [Sections 1081, 1082, and 1083]. This section would recommend that NIH and FDA facilitate global pediatric clinical networks by increasing the salaries of new investigators participating in such studies, as well as by engaging the European Medicines Agency and other foreign regulatory entities to encourage their participation in such networks. These initiatives could be funded by the NIH and Cures Innovation Fund, to be established by the Act. In addition, NIH would publish guidelines addressing under what justifications age should be an inclusion or exclusion criterion for research. NIH also would post on its website the number of children included in NIH-supported or conducted research, disaggregated by age group, race, and gender.

Prospects for the Legislation

Although the Cures Act has cleared the hurdle of the House, the prospects of passage in the Senate remain uncertain. The Senate Health, Education, Labor & Pensions Committee ("HELP Committee") has held numerous hearings over the past several months as it considers its own medical innovation legislation. However, the HELP Committee has not yet released even a discussion draft of its legislation, and one is not expected until at least the end of the Senate recess in August. Following the House's passage of the Cures Act, HELP Committee Chairman Lamar Alexander (R-TN) stated that the Senate's work would continue "on a parallel track . . . to produce a bill that [the Senate] can combine with 21st Century Cures and send to the President's desk."

Prior passage of the Cures Act, the White House, via a statement of administration policy, objected to the bill's use of the government's Strategic Petroleum Reserve to offset the bill's funding increases. The White House would have preferred that the bill directly address sequestration and ensure that FDA has sufficient funding to support all the programs established in the bill. The White House also expressed concern regarding the proposals relating to drug exclusivity and drug manufacturer communications with payors. Whether the Senate's proposed legislation will address the White House's concerns remains to be seen.

Re-authorization of the Prescription Drug User Fee Act ("PDUFA VI") is slated to occur in 2017. Given that PDUFA VI is considered "must-pass" legislation, it is possible that a number of issues under consideration in the Cures Act, particularly those issues lacking consensus, will be deferred until that latter debate.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions